Cargando…
Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Southern Society for Clinical Investigation. Published by Elsevier Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632263/ https://www.ncbi.nlm.nih.gov/pubmed/36335994 http://dx.doi.org/10.1016/j.amjms.2022.10.012 |
| _version_ | 1784823995958296576 |
|---|---|
| author | Garcia-Arellano, Gisela Camacho-Ortiz, Adrian Moreno-Arquieta, Ilse Andrea Cardenas-de la Garza, Jesus Alberto Rubio-Torres, Diana Carolina Garza-Gonzalez, Elvira Bocanegra-Ibarias, Paola Galarza-Delgado, Dionicio Angel |
| author_facet | Garcia-Arellano, Gisela Camacho-Ortiz, Adrian Moreno-Arquieta, Ilse Andrea Cardenas-de la Garza, Jesus Alberto Rubio-Torres, Diana Carolina Garza-Gonzalez, Elvira Bocanegra-Ibarias, Paola Galarza-Delgado, Dionicio Angel |
| author_sort | Garcia-Arellano, Gisela |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9632263 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Southern Society for Clinical Investigation. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96322632022-11-04 Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 Garcia-Arellano, Gisela Camacho-Ortiz, Adrian Moreno-Arquieta, Ilse Andrea Cardenas-de la Garza, Jesus Alberto Rubio-Torres, Diana Carolina Garza-Gonzalez, Elvira Bocanegra-Ibarias, Paola Galarza-Delgado, Dionicio Angel Am J Med Sci Letter to the Editor Southern Society for Clinical Investigation. Published by Elsevier Inc. 2023-02 2022-11-03 /pmc/articles/PMC9632263/ /pubmed/36335994 http://dx.doi.org/10.1016/j.amjms.2022.10.012 Text en © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Garcia-Arellano, Gisela Camacho-Ortiz, Adrian Moreno-Arquieta, Ilse Andrea Cardenas-de la Garza, Jesus Alberto Rubio-Torres, Diana Carolina Garza-Gonzalez, Elvira Bocanegra-Ibarias, Paola Galarza-Delgado, Dionicio Angel Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title | Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title_full | Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title_fullStr | Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title_full_unstemmed | Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title_short | Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19 |
| title_sort | anticardiolipin and anti-beta-2 glycoprotein i antibodies in patients with moderate or severe covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632263/ https://www.ncbi.nlm.nih.gov/pubmed/36335994 http://dx.doi.org/10.1016/j.amjms.2022.10.012 |
| work_keys_str_mv | AT garciaarellanogisela anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT camachoortizadrian anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT morenoarquietailseandrea anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT cardenasdelagarzajesusalberto anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT rubiotorresdianacarolina anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT garzagonzalezelvira anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT bocanegraibariaspaola anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 AT galarzadelgadodionicioangel anticardiolipinandantibeta2glycoproteiniantibodiesinpatientswithmoderateorseverecovid19 |